BOSTON, Mass. and SEATTLE, Wash. – May 25, 2023 – Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that preclinical data for its oncogenic driver program targeting KRAS G12V, AFNT–211, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, June 2-6.
“We are pleased to present novel preclinical data from our cell therapy targeting KRAS G12V, highlighting the robust stemness properties of our cell product as a key aspect of its comprehensive characterization. These findings establish a solid research foundation and support our ongoing effort to advance the program as a potential paradigm-shifting treatment for solid tumors,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. “Along with our collaborators, we will continue to push forward treatments targeting oncogenic driver mutations and look forward to presenting these findings at ASCO in Chicago.”
Poster presentation details are as follows:
- Developmental Therapeutics—Immunotherapy, Hall A, Abstract: 2543, Poster Board: 385, June 3 at 8 am CT / 9 am ET: AFNT-211: A FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors – Presenting Authors: Thomas Schmitt, Ph.D., Fred Hutchinson Cancer Center and Scientific Co-Founder, Affini-T Therapeutics and Hue Lam, Ph.D., Vice President, Preclinical Development, Affini-T Therapeutics
“With the THRIVETM T cell manufacturing platform, we can generate high yields of drug product exhibiting naïve and central memory phenotypes, enhancing the activity of this therapy,” said Kim Nguyen, Ph.D., Chief Technical Officer, Affini-T Therapeutics. “Our IND-enabling studies have demonstrated potent and specific pharmacological action with a rigorous toxicology profile that support the advancement of the AFNT-211 program to the clinic.”
About Affini-T Therapeutics
Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology, and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.
Ailsa Dalgliesh, PhD